AE

Aethlon Medical IncNASDAQ AEMD Stock Report

Last reporting period 31 Dec, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

AEMD Stock Analysis

AE

Uncovered

Aethlon Medical Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

10/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

22.969 B

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 14 full-time employees. The firm is focused on developing products to diagnose and treat life and organ-threatening diseases. The company is involved in developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seeding the spread of metastasis. The firm is conducting clinical trials in patients with advanced and metastatic head and neck cancer. The company is focused on the treatment of solid tumors that are being treated with checkpoint inhibitors. Hemopurifier have been used to treat individuals infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and Ebola.

View Section: Eyestock Rating